Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine

Translational Psychiatry

Volumn 6, Issue 4, 2016, Pages

  Hudson, M R ^a   Rind, G ^a   O'brien T J ^a   Jones, N C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; CLOZAPINE; DEXTRO SERINE; DIZOCILPINE; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; OLANZAPINE; AMINO ACID; BENZODIAZEPINE DERIVATIVE; DIZOCILPINE MALEATE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ELECTROENCEPHALOGRAPHY; MALE; NONHUMAN; OSCILLATION; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SENSORY GATING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; PATHOPHYSIOLOGY; STARTLE REFLEX; WISTAR RAT;

AMINO ACIDS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CLOZAPINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ELECTROENCEPHALOGRAPHY; HALOPERIDOL; KETAMINE; MALE; PREPULSE INHIBITION; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; REFLEX, STARTLE; SCHIZOPHRENIA;

EID: 85018400857     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.51     Document Type: Article

References (60)

1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41.
2. Weiss E, Kemmler G, Fleischhacker WW. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics. Arch Gen Psychiatry 2002; 59: 572–573, author reply 573–575.
3. Meltzer HY. Role of clozapine in treatment-resistant schizophrenia. In: Elkis H, Meltzer HY (eds). Advances in Biological Psychiatry: Therapy-Resistant Schizo-phrenia, vol. 26. Karger: Basel, Switzerland, 2000, pp 114–128.
4. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004; 72: 21–28.
5. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33: 523–533.
6. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646–1649.
7. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199–214.
8. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4–15.
9. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010; 128: 419–432.
10. Herrmann CS, Munk MHJ, Engel AK. Cognitive functions of gamma-band activity: memory match and utilization. Trends Cogn Sci 2004; 8: 347–355.
11. Tallon-Baudry C, Bertrand O. Oscillatory gamma activity in humans and its role in object representation. Trends Cogn Sci 1999; 3: 151–162.
12. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizo-phrenia. Nat Rev Neurosci 2010; 11: 100–113.
13. Spencer KM. Baseline gamma power during auditory steady-state stimulation in schizophrenia. Front Hum Neurosci 2011; 5: 190.
14. Baldeweg T, Spence S, Hirsch SR, Gruzelier J. Gamma-band electroencephalo-graphic oscillations in a patient with somatic hallucinations. Lancet 1998; 352: 620–621.
15. Behrendt RP. Hallucinations: synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn 2003; 12: 413–451.
16. Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch Gen Psychiatry 1999; 56: 1001–1005.
17. Leicht G, Kirsch V, Giegling I, Karch S, Hantschk I, Moller HJ et al. Reduced early auditory evoked gamma-band response in patients with schizophrenia. Biol Psychiatry 2010; 67: 224–231.
18. Hakami T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of con-sciousness. PLoS One 2009; 4: e6755.
19. Kocsis B. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 2012; 71: 987–995.
20. Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2010; 35: 632–640.
21. Kulikova SP, Tolmacheva EA, Anderson P, Gaudias J, Adams BE, Zheng T et al. Opposite effects of ketamine and deep brain stimulation on rat thalamocortical information processing. Eur J Neurosci 2012; 36: 3407–3419.
22. Anderson P, Jones NC, O'Brien TJ, Pinault D. The N-methyl D-aspartate glutamate receptor antagonist ketamine disrupts the functional state of the corticothalamic pathway (resubmitted).
23. Jones NC, Anderson P, Rind G, Sullivan C, van den Buuse M, O'Brien TJ. Effects of aberrant gamma frequency oscillations on prepulse inhibition. Int J Neu-ropsychopharmacol 2014; 17: 1671–1681.
24. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neu-roscience 2009; 158: 705–712.
25. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharma-cology 2001; 156: 234–258.
26. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999; 42: 1027–1040.
27. Jones NC, Reddy M, Anderson P, Salzberg MR, O'Brien TJ, Pinault D. Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power. Int J Neuropsychopharmacol 2012; 15: 657–668.
28. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697–706.
29. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 1998; 95: 15730–15734.
30. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego, CA, USA, 1998.
31. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T et al. Glycine and d-serine, but not d-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology 2008; 198: 363–374.
32. Shimazaki T, Kaku A, Chaki S. d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 2010; 209: 263–270.
33. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001; 156: 117–154.
34. Pantev C, Makeig S, Hoke M, Galambos R, Hampson S, Gallen C. Human auditory evoked gamma-band magnetic fields. Proc Natl Acad Sci USA 1991; 88: 8996–9000.
35. Hong LE, Summerfelt A, McMahon RP, Thaker GK, Buchanan RW. Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport 2004; 15: 155–159.
36. Hirano S, Hirano Y, Maekawa T, Obayashi C, Oribe N, Kuroki T et al. Abnormal neural oscillatory activity to speech sounds in schizophrenia: a magnetoencephalography study. J Neurosci 2008; 28: 4897–4903.
37. Lee K-H, Williams LM, Haig A, Goldberg E, Gordon E. An integration of 40 Hz Gamma and phasic arousal: novelty and routinization processing in schizo-phrenia. Clin Neurophysiol 2001; 112: 1499–1507.
38. Roach BJ, Mathalon DH. Event-related EEG time-frequency analysis: an overview of measures and an analysis of early gamma band phase locking in schizophrenia. Schizophr Bull 2008; 34: 907–926.
39. Teale P, Collins D, Maharajh K, Rojas DC, Kronberg E, Reite M. Cortical source estimates of gamma band amplitude and phase are different in schizophrenia. Neuroimage 2008; 42: 1481–1489.
40. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR et al. Original article: gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 2006; 60: 1231–1240.
41. Gandal MJ, Edgar JC, Klook K, Siegel SJ. Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuro-pharmacology 2012; 62: 1504–1518.
42. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl) 1995; 122: 198–201.
43. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schi-zophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 173–180.
44. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neu-ropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457–472.
45. Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005; 80: 591–596.
46. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233–255.
47. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–1028.
48. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neu-ropsychopharmacology 1996; 14: 87–96.
49. Olszewski M, Piasecka J, Goda SA, Kasicki S, Hunt MJ. Antipsychotic compounds differentially modulate high-frequency oscillations in the rat nucleus accumbens: a comparison of first-and second-generation drugs. Int J Neuropsychopharmacol 2013; 16: 1009–1020.
50. Anderson PM, Pinault D, O'Brien TJ, Jones NC. Chronic administration of anti-psychotics attenuates ongoing and ketamine-induced increases in cortical gamma oscillations. Int J Neuropsychopharmacol 2014; 17: 1895–1904.
51. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in pre-pulse inhibition of startle and its disruption by apomorphine. Psychopharmacol-ogy (Berl) 1995; 122: 35–43.
52. Lee H, Dvorak D, Kao HY, Duffy AM, Scharfman HE, Fenton AA. Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model. Neuron 2012; 75: 714–724.
53. Le Pen G, Moreau JL. Disruption of prepulse inhibition of startle reflex in a neu-rodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002; 27: 1–11.
54. Karasawa J, Hashimoto K, Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008; 186: 78–83.
55. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ. Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neuro-chemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 2006; 84: 392–399.
56. McCaughran J Jr, Mahjubi E, Decena E, Hitzemann R. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and pre-pulse inhibition. Psychopharmacology (Berl) 1997; 134: 131–139.
57. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical anti-psychotic treatment. Am J Psychiatry 2006; 163: 600–610.
58. Gallhofer B, Bauer U, Lis S, Krieger S. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6: 2–13.
59. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996; 47: 41–45.
60. Meyer-Lindenberg A, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997; 30: 35–42.